Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy

Creative Commons License

Ebik B., Aygan M., Tuncel E. T., Kacmaz H., Ekin N., ARPA M., ...More

HEPATOLOGY FORUM, vol.3, no.3, pp.82-87, 2022 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 3 Issue: 3
  • Publication Date: 2022
  • Doi Number: 10.14744/hf.2022.2022.0016
  • Journal Name: HEPATOLOGY FORUM
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.82-87
  • Keywords: Chronic Hepatitis C infection, direct-acting antiviral agents, hepatocellular carcinoma, VIROLOGICAL RESPONSE, ADVANCED FIBROSIS, CIRRHOSIS, INTERFERON/RIBAVIRIN, RECURRENCE, OUTCOMES, HCC
  • Recep Tayyip Erdoğan University Affiliated: Yes


Background and Aim: Several studies have suggested that treatment with direct-acting antivirals (DAAs) in patients with chronic hepatitis C virus (HCV) may be associated with an increased risk of developing hepatocellular carcinoma (HCC). We investigated the incidence and risk factors of HCC in HCV patients who achieved a sustained virologic response (SVR) following DAA therapies.